ATE477243T1 - 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten - Google Patents

2-aminochinoline als 5-ht(5a)- rezeptorantagonisten

Info

Publication number
ATE477243T1
ATE477243T1 AT07847380T AT07847380T ATE477243T1 AT E477243 T1 ATE477243 T1 AT E477243T1 AT 07847380 T AT07847380 T AT 07847380T AT 07847380 T AT07847380 T AT 07847380T AT E477243 T1 ATE477243 T1 AT E477243T1
Authority
AT
Austria
Prior art keywords
aminoquinolines
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT07847380T
Other languages
English (en)
Inventor
Sabine Kolczewski
Claus Riemer
Lucinda Steward
Juergen Wichmann
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE477243T1 publication Critical patent/ATE477243T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07847380T 2006-12-07 2007-11-27 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten ATE477243T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125604 2006-12-07
PCT/EP2007/062853 WO2008068157A1 (en) 2006-12-07 2007-11-27 2-aminoquinolines as 5-ht(5a) receptor antagonists

Publications (1)

Publication Number Publication Date
ATE477243T1 true ATE477243T1 (de) 2010-08-15

Family

ID=39033366

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07847380T ATE477243T1 (de) 2006-12-07 2007-11-27 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten

Country Status (18)

Country Link
US (1) US7923561B2 (de)
EP (1) EP2099763B1 (de)
JP (1) JP5031846B2 (de)
KR (1) KR101107807B1 (de)
CN (1) CN101541753B (de)
AR (1) AR064134A1 (de)
AT (1) ATE477243T1 (de)
AU (1) AU2007329064C1 (de)
BR (1) BRPI0720078A2 (de)
CA (1) CA2669590A1 (de)
CL (1) CL2007003481A1 (de)
DE (1) DE602007008469D1 (de)
ES (1) ES2348208T3 (de)
IL (1) IL198542A0 (de)
MX (1) MX2009005509A (de)
PE (1) PE20081446A1 (de)
TW (1) TW200845985A (de)
WO (1) WO2008068157A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007147762A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
WO2008068157A1 (en) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht(5a) receptor antagonists
WO2009109477A1 (en) * 2008-03-05 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinolines
CN101959864A (zh) 2008-03-07 2011-01-26 弗·哈夫曼-拉罗切有限公司 2-氨基喹啉衍生物
JP2011513352A (ja) * 2008-03-07 2011-04-28 エフ.ホフマン−ラ ロシュ アーゲー 5−ht(5a)受容体アンタゴニストとしての2−アミノキノリン誘導体
EP2328881A1 (de) * 2008-09-08 2011-06-08 F. Hoffmann-La Roche AG 5-substituierte benzoxazine
ES2734552T3 (es) 2010-04-16 2019-12-10 Ac Immune Sa Compuestos novedosos para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
WO2023034510A1 (en) 2021-09-01 2023-03-09 ATAI Life Sciences AG Synthesis of mdma or its optically active ( r)- or ( s)-mdma isomers
US11845736B2 (en) 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087845A2 (en) * 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
AU2003284217A1 (en) 2002-10-16 2004-05-04 Smithkline Beecham Corporation Chemical compounds
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
NZ560917A (en) * 2005-03-31 2011-01-28 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives
TWI291826B (en) * 2006-02-27 2007-12-21 Inventec Appliances Corp Method for activating different functions of hot key at different time and the device thereof
KR101088451B1 (ko) 2006-09-28 2011-12-01 에프. 호프만-라 로슈 아게 5-ht 결합 특성을 갖는 퀴놀린 유도체
WO2008068157A1 (en) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht(5a) receptor antagonists
JP2011513352A (ja) * 2008-03-07 2011-04-28 エフ.ホフマン−ラ ロシュ アーゲー 5−ht(5a)受容体アンタゴニストとしての2−アミノキノリン誘導体

Also Published As

Publication number Publication date
CA2669590A1 (en) 2008-06-12
JP5031846B2 (ja) 2012-09-26
CL2007003481A1 (es) 2008-07-04
EP2099763A1 (de) 2009-09-16
DE602007008469D1 (de) 2010-09-23
US20080146567A1 (en) 2008-06-19
CN101541753A (zh) 2009-09-23
AR064134A1 (es) 2009-03-11
PE20081446A1 (es) 2008-10-18
BRPI0720078A2 (pt) 2013-12-24
EP2099763B1 (de) 2010-08-11
WO2008068157A1 (en) 2008-06-12
TW200845985A (en) 2008-12-01
MX2009005509A (es) 2009-06-03
AU2007329064B2 (en) 2012-08-02
US7923561B2 (en) 2011-04-12
IL198542A0 (en) 2010-02-17
KR20090080545A (ko) 2009-07-24
AU2007329064A1 (en) 2008-06-12
JP2010511653A (ja) 2010-04-15
AU2007329064C1 (en) 2013-01-17
KR101107807B1 (ko) 2012-01-25
CN101541753B (zh) 2012-06-13
ES2348208T3 (es) 2010-12-01

Similar Documents

Publication Publication Date Title
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
DE602007008469D1 (de) 2-aminochinoline als 5-ht(5a)-rezeptorantagonisten
EP1981902A4 (de) Nogo-rezeptorantagonisten
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
EP2150115A4 (de) Cyclopropylpyrrolidinorexin-rezeptorantagonisten
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
DK2009992T3 (da) Il-8 receptor-antagonister
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
DK2081951T3 (da) Progesteron-receptorantagonister
ATE524460T1 (de) Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
BRPI0910592A2 (pt) antagonistas de receptor 2 de somatostatina
ATE517100T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE519738T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten
DK2370441T3 (da) Arylcyclohexylethere af dihydrotetraazabenzoazulener til anvendelse som vasopressin v1a-receptorantagonister
ATE534628T1 (de) Urotensin ii-rezeptorantagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2099763

Country of ref document: EP